Neurogene Inc. (NGNE)Healthcare | Biotechnology | New York, United States | NasdaqGM
27.85 USD
+2.22
(8.662%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 27.95 +0.10 (0.359%) ⇧ (April 17, 2026, 6:03 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:15 p.m. EDT
NGNE is a high-risk stock with a significant short ratio and negative earnings, indicating potential volatility and uncertainty. The recent price movements show a range-bound pattern with no clear trend, and insider selling suggests possible pessimism. While the company has some promising developments in gene therapy, the lack of dividends and negative fundamentals make it a risky proposition for both short-term and long-term investors. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.090415 |
| MSTL | 0.090967 |
| AutoETS | 0.091118 |
| AutoTheta | 0.215513 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.609 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.734 |
| Market Cap | 434,899,648 |
| Forward P/E | -5.02 |
| Beta | 1.89 |
| Website | https://www.neurogene.com |
As of April 11, 2026, 4:15 p.m. EDT: Options activity shows mixed signals. The calls and puts have varying levels of open interest and implied volatility, with some strikes showing higher IV and OI, suggesting potential for price movement. The recent volatility and insider selling might indicate uncertainty. However, the lack of significant long-term options activity could imply limited speculation on major price moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3169718 |
| Address1 | 535 W 24th Street |
| Address2 | 5th Floor |
| All Time High | 1,115.0 |
| All Time Low | 6.875 |
| Ask | 28.13 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 184,360 |
| Average Daily Volume3 Month | 168,906 |
| Average Volume | 168,906 |
| Average Volume10Days | 184,360 |
| Beta | 1.893 |
| Bid | 27.57 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 17.101 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.85 |
| Current Ratio | 16.56 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 29.05 |
| Day Low | 26.19 |
| Debt To Equity | 3.734 |
| Display Name | Neurogene |
| Earnings Timestamp | 1,774,355,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -100,116,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.744 |
| Enterprise Value | 174,622,064 |
| Eps Current Year | -5.006 |
| Eps Forward | -5.54333 |
| Eps Trailing Twelve Months | -4.24 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.479 |
| Fifty Day Average Change | 7.3710003 |
| Fifty Day Average Change Percent | 0.3599297 |
| Fifty Two Week Change Percent | 131.69717 |
| Fifty Two Week High | 37.266 |
| Fifty Two Week High Change | -9.415998 |
| Fifty Two Week High Change Percent | -0.25266996 |
| Fifty Two Week Low | 11.27 |
| Fifty Two Week Low Change | 16.58 |
| Fifty Two Week Low Change Percent | 1.4711623 |
| Fifty Two Week Range | 11.27 - 37.266 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,394,202,600,000 |
| Float Shares | 5,102,138 |
| Forward Eps | -5.54333 |
| Forward P E | -5.024056 |
| Free Cashflow | -46,465,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 131 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -74,891,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09001 |
| Held Percent Institutions | 1.08474 |
| Implied Shares Outstanding | 15,615,786 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,702,944,000 |
| Last Split Factor | 1:4 |
| Long Business Summary | Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. |
| Long Name | Neurogene Inc. |
| Market | us_market |
| Market Cap | 434,899,648 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_602062523 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -90,351,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 435,524,271 |
| Number Of Analyst Opinions | 6 |
| Open | 26.19 |
| Operating Cashflow | -77,173,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 855 508 3568 |
| Post Market Change | 0.10000038 |
| Post Market Change Percent | 0.3590678 |
| Post Market Price | 27.95 |
| Post Market Time | 1,776,463,394 |
| Previous Close | 25.63 |
| Price Eps Current Year | -5.563324 |
| Price Hint | 2 |
| Price To Book | 1.6285598 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.42 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 2.22 |
| Regular Market Change Percent | 8.66173 |
| Regular Market Day High | 29.05 |
| Regular Market Day Low | 26.19 |
| Regular Market Day Range | 26.19 - 29.05 |
| Regular Market Open | 26.19 |
| Regular Market Previous Close | 25.63 |
| Regular Market Price | 27.85 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 324,429 |
| Return On Assets | -0.20663999 |
| Return On Equity | -0.31412 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 15,615,786 |
| Shares Percent Shares Out | 0.2587 |
| Shares Short | 4,029,257 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,673,771 |
| Short Name | Neurogene Inc. |
| Short Percent Of Float | 0.3211 |
| Short Ratio | 22.86 |
| Source Interval | 15 |
| State | NY |
| Symbol | NGNE |
| Target High Price | 180.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 77.66667 |
| Target Median Price | 60.0 |
| Total Cash | 269,012,992 |
| Total Cash Per Share | 17.273 |
| Total Debt | 9,891,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.527075 |
| Two Hundred Day Average Change | 6.3229256 |
| Two Hundred Day Average Change Percent | 0.29371968 |
| Type Disp | Equity |
| Volume | 324,429 |
| Website | https://www.neurogene.com |
| Zip | 10,011 |